Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
University Hospitals of Cleveland, Cleveland, Ohio, USA.
JACC Cardiovasc Interv. 2023 Jul 10;16(13):1626-1635. doi: 10.1016/j.jcin.2023.05.004.
The latest-generation Evolut FX TAVR system (Medtronic) offers several potential design improvements over its predecessors, but early reported experience has been limited.
This study sought to report our multicenter, limited market release, first-in-human experience of transcatheter aortic valve replacement (TAVR) with the Evolut FX system and compare it with a single-center PRO+ (Medtronic) experience.
From June 27 to September 16, 2022, 226 consecutive patients from 9 US centers underwent transfemoral TAVR with the Evolut FX system for native aortic stenosis (89.4%) or prosthetic valve degeneration (10.6%). Commissural alignment was defined as 0° to 30° between native and FX commissures. Patient, anatomical, and procedural characteristics were retrospectively reviewed, and 30-day clinical and echocardiographic outcomes per Valve Academic Research Consortium-3 definitions were reported.
Of 226 patients, 34.1% were low risk, 4% had a bicuspid valve, and 11.5% had a horizontal root (≥60°). Direct Inline sheath (Medtronic) was used in 67.6% and Lunderquist stiff wire (Cook Medical) in 35.4% of cases. Optimal hat marker orientation during deployment was achieved in 98.4%, with commissural alignment in 96.5%. At 30 days, 14.3% mild, 0.9% moderate, and no severe paravalvular leak were observed. Compared with the Evolut PRO+ experience from 1 center, FX had a more symmetrical implantation with shallower depth at the left coronary cusp (P < 0.001), fewer device recaptures (26.1% vs 39.5%; P = 0.004), and improved commissural alignment (96.5% vs 80.2%; P < 0.001).
The Evolut FX system demonstrated favorable 30-day outcomes with a significant improvement over PRO+ in achieving commissural alignment, fewer device recaptures, and more symmetrical implantation. These features may benefit younger patients undergoing TAVR with the supra-annular, self-expanding valve, where lifetime management would be important.
新一代 Evolut FX TAVR 系统(美敦力)相较于前代产品具有多项潜在设计改进,但目前早期报道的经验有限。
本研究旨在报告我们多中心、有限市场发布的首例经导管主动脉瓣置换术(TAVR)使用 Evolut FX 系统的经验,并与单中心 PRO+(美敦力)经验进行比较。
2022 年 6 月 27 日至 9 月 16 日,来自美国 9 个中心的 226 例连续患者采用经股动脉途径行 Evolut FX 系统 TAVR,适应证为原发性主动脉瓣狭窄(89.4%)或人工瓣膜退行性变(10.6%)。交界对位定义为 0°至 30°。回顾性分析患者、解剖和手术特点,并按 Valve Academic Research Consortium-3 定义报告 30 天临床和超声心动图结果。
226 例患者中,34.1%为低危患者,4%为二叶瓣,11.5%为水平型主动脉根部(≥60°)。67.6%采用直接直线型鞘管(美敦力),35.4%采用 Lunderquist 硬导丝(库克医疗)。98.4%在释放过程中实现了最佳的瓣膜帽标记定向,96.5%实现了交界对位。30 天时,14.3%为轻度,0.9%为中度,无严重瓣周漏。与单中心 Evolut PRO+经验相比,FX 具有更对称的植入,左冠状动脉瓣更浅(P<0.001),更少的器械重捕(26.1% vs 39.5%;P=0.004),交界对位更好(96.5% vs 80.2%;P<0.001)。
Evolut FX 系统在实现交界对位、减少器械重捕和更对称植入方面较 PRO+有显著改善,30 天结果良好。这些特点可能使接受瓣环上、自膨式瓣膜 TAVR 的年轻患者受益,而长期管理对这类患者很重要。